IBDEI0UO ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15129,0)
 ;;=203.00^^89^902^103
 ;;^UTILITY(U,$J,358.3,15129,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15129,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,15129,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,15129,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,15130,0)
 ;;=203.01^^89^902^105
 ;;^UTILITY(U,$J,358.3,15130,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15130,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,15130,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,15130,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,15131,0)
 ;;=238.6^^89^902^108
 ;;^UTILITY(U,$J,358.3,15131,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15131,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,15131,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,15131,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,15132,0)
 ;;=205.00^^89^902^4
 ;;^UTILITY(U,$J,358.3,15132,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15132,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,15132,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,15132,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,15133,0)
 ;;=205.01^^89^902^6
 ;;^UTILITY(U,$J,358.3,15133,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15133,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,15133,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,15133,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,15134,0)
 ;;=205.10^^89^902^19
 ;;^UTILITY(U,$J,358.3,15134,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15134,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,15134,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,15134,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,15135,0)
 ;;=205.11^^89^902^21
 ;;^UTILITY(U,$J,358.3,15135,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15135,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,15135,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,15135,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,15136,0)
 ;;=289.0^^89^902^55
 ;;^UTILITY(U,$J,358.3,15136,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15136,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,15136,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,15136,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,15137,0)
 ;;=238.4^^89^902^109
 ;;^UTILITY(U,$J,358.3,15137,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15137,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,15137,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,15137,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,15138,0)
 ;;=V58.61^^89^902^126
 ;;^UTILITY(U,$J,358.3,15138,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15138,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,15138,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,15138,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,15139,0)
 ;;=282.49^^89^902^117
 ;;^UTILITY(U,$J,358.3,15139,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15139,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,15139,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,15139,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,15140,0)
 ;;=289.89^^89^902^15
 ;;^UTILITY(U,$J,358.3,15140,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15140,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,15140,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,15140,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,15141,0)
 ;;=238.79^^89^902^88
 ;;^UTILITY(U,$J,358.3,15141,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15141,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,15141,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,15141,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,15142,0)
 ;;=287.30^^89^902^110
 ;;^UTILITY(U,$J,358.3,15142,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15142,1,4,0)
 ;;=4^287.30
